|
See related Symbicort Turbuhaler information |
|
|
|
Manufacturer |
AstraZeneca |
|
Distributor |
Hong Kong: Zuellig/Macau: Four Star |
|
Contents |
Per 80/4.5 mcg turbuhaler Budesonide 80 mcg, formoterol 4.5 mcg. Per 160/4.5 mcg turbuhaler Budesonide 160 mcg, formoterol 4.5 mcg. Per 320/9 mcg turbuhaler Budesonide 320 mcg, formoterol 9 mcg |
|
Indications |
Regular treatment of asthma where use of a combination (inhaled corticosteroid & long-acting β2-agonist) is appropriate. Symptomatic treatment of severe COPD.
Click to view Symbicort Turbuhaler detailed prescribing infomation |
|
Dosage |
Asthma 80/4.5 mcg & 160/4.5 mcg turbuhaler Adult ≥18 yr 1-2 inhalations bd. Max: 4 inhalations bd. Adolescent 12-17 yr 1-2 inhalations bd. 80/4.5 mcg turbuhaler Childn ≥6 yr 2 inhalations bd. 320/9 mcg turbuhaler Adult ≥18 yr 1 inhalation bd. Max: 2 inhalations bd. Adolescent 12-17 yr 1 inhalation bd. Maintenance & reliever therapy 80/4.5 mcg & 160/4.5 mcg turbuhaler Adult ≥18 yr 1-2 inhalations bd. Max: 8 inhalations/day; 12 inhalations/day could be used for a limited period. COPD Adult 160/4.5 mcg turbuhaler 2 inhalations bd. 320/9 mcg turbuhaler 1 inhalation bd.
Click to view Symbicort Turbuhaler detailed prescribing infomation |
|
Overdosage |
View Symbicort Turbuhaler overdosage for action to be taken in the event of an overdose. |
|
Contraindications |
Hypersensitivity to lactose.
Click to view Symbicort Turbuhaler detailed prescribing infomation |
|
Special Precautions |
In patients whose asthma cannot be controlled by other medications, long-term use is considered. Appropriate only for patients where combination of inhaled corticosteroids & β2-agonist is permitted. Use for the shortest time required to achieve control of asthma symptoms. Consider discontinuation & test of inhaled costicosteroid when long-term control of asthma is maintained w/ lowest dose. Acute or initial management of asthma. Taper dose when discontinuing treatment. Not for regular prophylactic use. Thyrotoxicosis, phaeochromocytoma, DM, untreated hypokalaemia, hypertrophic obstructive cardiomyopathy, idiopathic subvalvular aortic stenosis, severe HTN, aneurysm, severe CV disorders, quiescent pulmonary TB, fungal & viral infections in the airways. If oropharyngeal thrush occurs, rinse mouth w/ water after inhalations. Pregnancy & lactation.
Click to view Symbicort Turbuhaler detailed prescribing infomation |
|
Adverse Drug Reactions |
Headache, candida infections in the oropharynx, palpitations, tremor, mild throat irritation, cough, hoarseness.
View ADR Monitoring Form |
|
Drug Interactions |
CYP450 3A4 inhibitors (eg itraconazole, ritonavir), CYP3A4 inhibitors, β-blockers, quinidine, disopyramide, procainamide, phenothiazines, terfenadine, MAOIs, TCA, levodopa, l-thyroxine, oxytocin, alcohol.
View more drug interactions with Symbicort Turbuhaler |
|
Pregnancy Category (US FDA) |
Category C: Either studies in animals have revealed adverse effects on the foetus (teratogenic or embryocidal or other) and there are no controlled studies in women or studies in women and animals are not available. Drugs should be given only if the potential benefit justifies the potential risk to the foetus. |
|
Storage |
View Symbicort Turbuhaler storage conditions for details to ensure optimal shelf-life. |
|
Description |
View Symbicort Turbuhaler description for details of the chemical structure and excipients (inactive components). |
|
Mechanism of Action |
View Symbicort Turbuhaler mechanism of action for pharmacodynamics and pharmacokinetics details. |
|
